New Age Alpha Advisors LLC Grows Stake in IDEXX Laboratories, Inc. $IDXX

New Age Alpha Advisors LLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10,065.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,066 shares of the company’s stock after purchasing an additional 4,026 shares during the period. New Age Alpha Advisors LLC’s holdings in IDEXX Laboratories were worth $2,598,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in IDXX. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at approximately $31,000. Armstrong Advisory Group Inc. boosted its position in shares of IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after acquiring an additional 19 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in IDEXX Laboratories during the third quarter valued at $35,000. Greykasell Wealth Strategies Inc. bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $35,000. Finally, WealthCollab LLC bought a new stake in IDEXX Laboratories in the 2nd quarter valued at $30,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $636.70 on Tuesday. The firm has a market capitalization of $50.69 billion, a PE ratio of 48.71, a PEG ratio of 3.99 and a beta of 1.66. The stock’s fifty day moving average is $671.64 and its 200 day moving average is $669.00. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm earned $2.53 EPS. The company’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Activity at IDEXX Laboratories

In other news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the transaction, the chief executive officer owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. This represents a 21.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the sale, the director owned 648 shares in the company, valued at approximately $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 44,199 shares of company stock worth $28,746,535 in the last three months. 0.98% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on IDXX. Wall Street Zen downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday. Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, January 29th. Piper Sandler cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. BTIG Research decreased their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $830.00 target price on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $783.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.